Pharma News
17 Aug 2025 to 23 Aug 2025
Aug 23, 2025
Why are there counterfeit versions of Ozempic, Zepbound, Wegovy, and Mounjaro available online? : Planet Money - NPR
Phil, a former addict, found life-changing benefits from Ozempic, a diabetes drug, which helped him manage cravings and lose weight. However, after his insurance stopped covering it, he turned to cheaper alternatives online. This surge in demand has led to a parallel market for compounded versions of Ozempic and similar drugs, challenging traditional pharmaceutical sales.
Aug 23, 2025
Shingles Vaccine Associated with Reduced Risk of Stroke and Heart Attack in Individuals Aged 50 and Above
A recent study reveals that the recombinant shingles vaccine significantly reduces the risk of herpes zoster, herpes zoster ophthalmicus, and lowers hospitalization rates for stroke and heart attack in adults over 50. These findings suggest broader health benefits of the vaccine beyond shingles prevention, indicating a potential link to improved cardiovascular health in older adults.
Aug 23, 2025
The Locations of U.S. Drug Production and the Potential Impact of Trump's Tariffs
President Trump's threats to impose tariffs on imported medicines have raised questions about the production of drugs in the U.S. The process is complex, often involving multiple countries for raw materials and formulation. U.S. Pharmacopeia provided data to The New York Times, highlighting the intricate geography of drug shipments for American consumers.
Aug 22, 2025
The FDA's Challenge with Generic Medications: Finding a Balance Between Innovation and Market Consistency - AInvest
The FDA's expedited pathways for drug approvals have sparked controversy, particularly highlighted by Vanda Pharmaceuticals' legal battle over its drug Hetlioz. Critics argue that the agency's approach undermines branded drug patents and innovation. Recent court rulings may prompt greater scrutiny of FDA decisions, impacting the generic drug market and investor strategies in the biopharma sector.
Aug 22, 2025
Merakris receives notice of allowance from the USPTO for a key patent related to MTX-001.
Merakris Therapeutics announced that the USPTO has issued a Notice of Allowance for US Patent No. US-2022/0133806 A1, covering its method for isolating extracellular vesicles from amniotic fluid for wound healing. This patent strengthens the intellectual property for MTX-001, Merakris' lead investigational drug for chronic venous leg ulcers, currently in phase 2 clinical trials.
Aug 22, 2025
The Semaglutide Narrative: Emphasizing the Importance of Preserving Patent Rights in Canada
Novo Nordisk's semaglutide, marketed as Ozempic® and Wegovy®, may see generic competition in Canada by early 2026 due to a lapsed patent. This could lead to significant price reductions, saving millions in healthcare costs. The situation highlights the complexities of patent strategy and regulatory processes, with potential implications for drug pricing across North America and beyond.
Aug 22, 2025
Patent Extensions Result in $3.5 Billion Loss in Potential Generic Savings for the US
A study published in JAMA Health Forum reveals that overlapping patents for four top-selling drugs—imatinib (Gleevec; Novartis), glatiramer (Copaxone; Teca Pharmaceuticals), celecoxib (Celebrex; Pfizer), and bimatoprost (Lumigan; AbbVie)—delayed generic competition, resulting in an estimated $3.5 billion in excess spending over two years. The findings highlight the financial impact of patent strategies on drug costs.
Aug 22, 2025
Worldwide Generic Pharmaceuticals Market Projected to Hit $594.99 Billion by 2031, Expanding at a 5.0% Annual Growth Rate
The global generic drugs market is projected to grow from $423.55 billion in 2024 to $594.99 billion by 2031, with a CAGR of 5.0%. This growth is driven by patent expirations, rising demand for affordable medications, and the increasing popularity of biosimilars. North America leads in production and consumption, while developing regions invest in manufacturing to enhance healthcare accessibility.
Aug 22, 2025
Analysis: After significant growth fueled by Wegovy, Novo has expanded its staff, but layoffs are now on the horizon.
Novo Nordisk is rapidly expanding its manufacturing capacity and sales outreach for its popular weight-loss drug Wegovy, resulting in a hiring spree that has nearly doubled its workforce over the past five years.
Aug 22, 2025
Strengthening the Barrier: Novo Nordisk's Legal and Regulatory Strategies to Maintain Its GLP-1 Leadership
Novo Nordisk's semaglutide-based drugs, Wegovy® and Ozempic®, dominate the GLP-1 receptor agonist market, with U.S. sales reaching $28 billion in 2024. The company employs aggressive legal strategies, filing 132 lawsuits to protect its patents and deter competition. As it navigates global patent challenges, Novo's tactics aim to maintain its market dominance amid rising competition from generics and rivals like Eli Lilly.
Aug 22, 2025
Serena Williams is now the spokesperson for popular weight loss medications.
Tennis champion Serena Williams has become a spokesperson for a healthcare company, crediting GLP-1 medication Zepbound, made of tirzepatide, for her 31-pound weight loss post-pregnancy. While some question the need for such medication, experts emphasize that it can be safe when used under medical guidance, though results vary and require lifestyle support.
Aug 22, 2025
ABBV's Rising Oncology Revenue Positions It Favorably for Future Growth - TradingView
AbbVie (ABBV) has strengthened its oncology portfolio with recent approvals of Epkinly and Emrelis, alongside the acquisition of Elahere. The oncology segment generated $3.3 billion in the first half of 2025, driven by new drug sales despite declining Imbruvica revenues. AbbVie’s stock has risen 21.2% this year, though it trades at a higher valuation compared to the industry.
Aug 22, 2025
Novo Nordisk Makes a Strong Comeback: Six Factors Fueling the Company's Rise to Leadership in Pharmaceuticals
Novo Nordisk (NVO) has rebounded with a 26.5% stock surge, driven by strategic initiatives and market dynamics. Key catalysts include Wegovy's new approval for treating liver disease, reduced tariffs, aggressive pricing strategies for Ozempic and Wegovy, and legal actions against compounders. Meanwhile, competitors like Eli Lilly (LLY) face setbacks, reinforcing NVO's dominant position in the GLP-1 market.
Aug 22, 2025
Understanding the GLP-1 Black Market: Assessing Its Potential Risks - Newsmax
A black market for GLP-1 weight-loss drugs, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), is endangering U.S. patients. Unauthorized knock-offs, often made with foreign ingredients, pose serious health risks, including overdoses and deaths. Lawmakers urge the FDA to intervene, as the illegal market undermines patient safety and threatens pharmaceutical innovation.
Aug 22, 2025
Delhi government reports that the majority of drug samples analyzed are authentic amid counterfeit cancer medication concerns.
The Delhi government reported that the majority of cancer drug samples tested from private pharmacies are genuine. Out of 160 samples collected in June, 127 were confirmed authentic, alleviating concerns over counterfeit medications.
Aug 22, 2025
24 bottles of prohibited oxytocin discovered at dairy facility; samples dispatched for analysis.
The Food Safety Department seized 24 banned bottles of oxytocin at a dairy in Jasnawali, Bulandshahr, following reports of counterfeit milk production. Samples have been sent for testing to investigate the matter further.
Aug 22, 2025
BioNxt accelerates US patent application for its multiple sclerosis treatment and obtains extensive intellectual property rights.
BioNxt Solutions Inc. has initiated the prioritized examination for its US patent application for BNT23001, a sublingual thin-film formulation of cladribine aimed at treating multiple sclerosis. The company also secured acceptance for a broad international patent protecting its delivery technology across various diseases. BioNxt's innovations target significant markets, including multiple sclerosis and generalized myasthenia gravis, with a combined potential of $42-46 billion by 2032.
Aug 21, 2025
Natco Pharma files lawsuit against Novo Nordisk in effort to promote generic medication - The Economic Times
Natco Pharma's lawyers revealed in court that the company has attempted to engage with Novo Nordisk regarding its non-infringing patents but has received no response. Experts suggest that a clear communication from Novo Nordisk could lead to a generic launch of Wegovy in India, potentially impacting its sales.
Aug 21, 2025
Evoke Pharma Reveals Inclusion of New GIMOTI® Patent in FDA's Orange Book - BioSpace
Evoke Pharma, Inc. announced that U.S. Patent No. 12,377,064 for GIMOTI® (metoclopramide) nasal spray has been listed in the FDA's Orange Book. This patent, expiring on November 17, 2038, supports Evoke's strategy to enhance GIMOTI's market presence for treating diabetic gastroparesis, reinforcing their commitment to innovation in gastrointestinal treatments.
Aug 21, 2025
What is the dispute between Natco Pharma and Novo Nordisk regarding a weight-loss patent in the Delhi High Court?
Novo Nordisk has sued Dr. Reddy’s Laboratories and OneSource Specialty Pharma over alleged patent violations related to its diabetes medication, semaglutide, marketed as Wegovy. The companies agreed not to sell their version of the anti-obesity drug in India while the lawsuit is pending. Dr. Reddy’s claims to have a license to manufacture the drug starting December 2024.
Aug 21, 2025
Key Trends Shaping the Oncology Biosimilars Market in 2025
The oncology biosimilars market is projected to grow from $6.9 billion in 2024 to $8.85 billion in 2025, driven by patent expirations and increased R&D investments. Companies like Biocon Biologics and Viatris are leading innovations, with products like Abevmy (bevacizumab) entering the market. The market is expected to reach $16.48 billion by 2029, reflecting a strong growth trajectory.
Aug 21, 2025
Promoting the right to health in cancer treatment by utilizing drug repurposing methods.
A recent perspective article highlights the benefits of drug repurposing in oncology, emphasizing its potential to reduce treatment development costs and promote global health equity. The strategy, which includes using off-patent non-cancer medicines and adding new indications to existing cancer drugs, can enhance access to care, particularly in low- and middle-income countries, while improving approval rates for treatments.
Aug 21, 2025
Can Johnson & Johnson Overcome Challenges from Stelara, Talc Lawsuits, Tariffs, and More? - TradingView
Johnson & Johnson (JNJ) faces significant challenges, including the loss of patent exclusivity for Stelara, which has led to a 42.7% sales decline in Q2 2025 due to biosimilar competition from companies like Amgen and Teva. Additionally, the Medicare Part D redesign is expected to impact sales by $2 billion. J&J also contends with over 62,000 talc lawsuits and potential tariffs on pharmaceutical imports.
Aug 21, 2025
Delhi High Court Orders Mediation in Wegovy Patent Conflict Between Natco and Novo Nordisk
Natco Pharma has filed a lawsuit against Novo Nordisk over its weight-loss drug Wegovy (semaglutide) in the Delhi High Court, claiming non-infringement of patents. The court has suggested pre-litigation mediation. Industry experts suggest Novo Nordisk's silence may be a tactic to protect Wegovy's market. The semaglutide patent expires in March 2026, potentially leading to a surge in generic competition.
Aug 21, 2025
FDA Makes Announcement Regarding Replimune Following Developments from Sarepta and Soleno in the Biotechnology Industry
The FDA has made a significant decision regarding Replimune, a company specializing in oncolytic immunotherapies, impacting the biotech sector. This news coincides with updates from Sarepta Therapeutics, known for gene therapies, and Soleno Therapeutics, focused on rare metabolic disorders, highlighting ongoing innovation in biotechnology and pharmaceuticals.
Aug 21, 2025
Dei BioPharma receives FDA approval in the $300 billion competition for diabetes and obesity medications - The Observer
Dei BioPharma has received FDA approval for its development plan to produce biosimilar versions of liraglutide and semaglutide, potentially transforming diabetes and obesity treatment in Uganda and beyond. The Kampala-based company aims to manufacture these GLP-1 agonists at affordable prices, challenging Western pharmaceutical giants. If successful, Dei could launch the drugs within 18 months, marking a significant milestone for African science.
Aug 21, 2025
The top pharmaceutical companies that faced significant losses in the first half of 2025 - PharmaVoice
In the first half of 2025, Merck & Co.'s Keytruda generated over $15 billion, while Eli Lilly's Trulicity saw a 19% sales drop to $2.2 billion due to competition from Mounjaro. Johnson & Johnson's Stelara fell 38% to $3.3 billion, and AbbVie's Humira dropped 55% to $2.3 billion. Roche's Herceptin sales decreased 21%, while AstraZeneca's Synagis fell to $162 million.
Aug 21, 2025
Novo Nordisk Halts Recruitment as Challenges Persist for Ozempic Manufacturer - Gizmodo
Novo Nordisk, the maker of Ozempic and Wegovy, has implemented a hiring freeze amid a declining financial outlook and increased competition from Eli Lilly's Zepbound. The company faces challenges from cheaper compounded versions of semaglutide and has lowered its sales growth projections. Layoffs are anticipated as Novo Nordisk navigates this turbulent period in the obesity treatment market.
Aug 21, 2025
VK Paul announces four upcoming treatments for rare diseases and five existing medications for seven conditions.
Four new drugs for rare diseases are set to launch soon, while five medications for seven ailments are already available, according to Dr. VK Paul, a member of Niti Aayog. This development aims to alleviate patient suffering in India.
Aug 21, 2025
DCGI reports that digitization at the drug regulatory agency accelerates the approval process, according to DrugsControl Media Services.
The DCGI, Rajeev Raghuvanshi, announced that the implementation of digital dashboards by the CDSCO has significantly expedited the drug approval process, leading to faster timelines for medical drug approvals.
Aug 21, 2025
Telangana Home Minister directs measures against deceptive pharmaceutical advertisements and the distribution of inferior medications.
Telangana Health Minister Damodar Rajanarsimha has directed the Drug Control Authority to take strict action against misleading pharmaceutical advertisements and the sale of substandard drugs. This initiative aims to ensure consumer safety and uphold industry standards in the state.
Aug 20, 2025
In 2026, increased employer healthcare expenses are being fueled by GLP-1 medications and cancer treatment.
A recent survey by the Business Group on Health reveals that employers expect health care costs to rise by a median of 9% next year, driven largely by increased use of GLP-1 drugs like Wegovy and Ozempic, as well as cancer treatment expenses. Employers are exploring strategies to manage these costs while attempting to shield employees from higher premiums.
Aug 20, 2025
AbbVie Sees 11.5% Increase Over the Past Month: Should You Buy, Hold, or Sell? - The Globe and Mail
AbbVie’s stock (ABBV) surged 11.5% following strong Q2 results, with earnings of $2.97 per share and revenues of $15.42 billion, driven by key drugs like Skyrizi and Rinvoq. Despite declining sales of Humira, AbbVie raised its 2025 revenue and EPS guidance. The company is also expanding its oncology and neuroscience portfolios through acquisitions and new drug launches.
Aug 20, 2025
Dismantling the Patent Barrier: The Potential Impact of the Suggested ETHIC Act on ...
U.S. Senators Peter Welch, Josh Hawley, and Amy Klobuchar introduced the ETHIC Act (S. 2276) on July 15, 2025, aiming to limit drug patent assertions by branded companies. The bill seeks to enhance competition and lower drug prices by allowing only one patent per Patent Group to be asserted against generic and biosimilar applicants, potentially easing market entry for these alternatives.
Aug 20, 2025
Enanta Pharmaceuticals Initiates Patent Infringement Lawsuit Against Pfizer - The Globe and Mail
Enanta Pharmaceuticals has filed a lawsuit against Pfizer Inc. in the Unified Patent Court of the EU, alleging infringement of its European Patent No. EP 4 051 265 related to the COVID-19 antiviral Paxlovid™ (nirmatrelvir and ritonavir). The patent was recently granted by the European Patent Office and is part of ongoing litigation in the U.S. regarding similar claims.
Aug 20, 2025
BioNxt Accelerates Patent Process for MS Treatment and Obtains Intellectual Property Safeguards for Its Platform | BNXTF Stock Update
BioNxt Solutions Inc. has fast-tracked its U.S. patent application for BNT23001, a sublingual thin-film formulation of cladribine for multiple sclerosis, under the USPTO's Track One Program. The company also secured a broad international patent for its drug delivery platform, enhancing its IP position for various autoimmune neurological disorders. BioNxt aims to improve patient compliance and bioavailability compared to Merck KGaA's MAVENCLAD®.
Aug 20, 2025
Q2 Earnings Summary: Viatris (NASDAQ:VTRS) and Other Generic Pharmaceutical Companies
In Q2, generic pharmaceutical stocks showed strong performance, with revenues surpassing estimates by 2.8%. Viatris (NASDAQ:VTRS) reported $3.58 billion in revenue, down 5.6% year-on-year, while ANI Pharmaceuticals (NASDAQ:ANIP) excelled with a 53.1% revenue increase. Amphastar Pharmaceuticals (NASDAQ:AMPH) and Amneal (NASDAQ:AMRX) had mixed results, with stock prices rising significantly post-earnings.
Aug 20, 2025
Enanta Pharmaceuticals Initiates Patent Infringement Lawsuit Against Pfizer in the Unified ... - Business Wire
Enanta Pharmaceuticals has filed a lawsuit against Pfizer Inc. in the European Union's Unified Patent Court, claiming infringement of its European Patent No. EP 4 051 265 related to the COVID-19 antiviral Paxlovid™ (nirmatrelvir and ritonavir). The patent was recently granted and is part of ongoing U.S. litigation between the two companies.
Aug 20, 2025
BioNxt Accelerates U.S. Patent Application for MS Treatment and Obtains Extensive Intellectual Property Protection for Platform...
BioNxt Solutions Inc. has initiated the prioritized examination for its U.S. patent application for BNT23001, a novel sublingual thin-film formulation of cladribine for multiple sclerosis. The company also secured acceptance for a broad international patent protecting its delivery technology. BioNxt aims to enhance patient compliance and bioavailability, targeting significant markets in autoimmune neurodegenerative diseases.
Aug 20, 2025
Enanta Pharmaceuticals Sues Pfizer for Alleged Patent Violation Related to COVID-19...
Enanta Pharmaceuticals has filed a patent infringement lawsuit against Pfizer regarding its COVID-19 drug, Paxlovid. Pfizer asserts confidence in its intellectual property rights for the medication, which has been crucial in treating COVID-19. This legal challenge adds to the scrutiny surrounding Pfizer's patents for Paxlovid, a key product for the company.
Aug 20, 2025
Eli Lilly Among Leading Large-Cap Companies as Sales of GLP-1 Medications Surpass Billion-Dollar Mark
Eli Lilly (NYSE: LLY) has emerged as a top performer in 2024, driven by strong sales of its GLP-1 drugs, including Mounjaro and Zepbound, which generated billions. Despite a decline in 2025, the company remains a key player in the healthcare sector, with established products like Trulicity and Verzenio, and promising future therapies like donanemab and mirikizumab.
Aug 20, 2025
Eli Lilly's Shares Soar Following Historic $6.75 Billion Bond Offering, Daily Trading Volume Places 17th in...
Eli Lilly (LLY) experienced a 0.74% stock price increase on August 19, 2025, amid a $6.75 billion corporate bond issuance, including a rare 40-year bond. The funds will support general corporate purposes and debt reduction. With projected revenues of $58-61 billion from drugs like Mounjaro and Zepbound, LLY's strong credit profile enhances its financial stability.
Aug 20, 2025
Madrigal Receives Conditional Approval for MASH Medication Rezdiffra in Europe - TradingView
Madrigal Pharmaceuticals (MDGL) received conditional marketing authorization from the European Commission for Rezdiffra (resmetirom), the first approved treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in the EU. The drug's launch is expected in Germany by Q4 2025. Despite this approval, MDGL shares fell 3% due to competition from Novo Nordisk's Wegovy (semaglutide).
Aug 19, 2025
Pfizer's Cancer Medications Boost Revenue in Q2: Is This Growth Sustainable? - TradingView
Pfizer (PFE) continues to strengthen its oncology portfolio, bolstered by the acquisition of Seagen, which added four antibody-drug conjugates (ADCs). Oncology sales grew 9% in the first half of 2025, driven by drugs like Xtandi and Padcev. Pfizer's future in cancer treatment looks promising, with expectations of eight blockbuster oncology medicines by 2030.
Aug 19, 2025
Innogen focuses on developing extended-duration GLP-1 medications to differentiate itself in a competitive market - Kr Asia
Innogen, a pharmaceutical company specializing in GLP-1 therapies, made a strong debut on the Hong Kong Stock Exchange, with shares soaring 200% and a market cap of RMB 26 billion. The company’s approved GLP-1 drug, efsubaglutide alfa (Diabegone), targets Type 2 diabetes and shows promise for weight loss. Innogen aims to leverage its long-acting formulation to compete in the growing GLP-1 market.
Aug 19, 2025
Could Ozempic for dogs be available in three years as a solution for pet obesity?
Pharmaceutical companies are developing weight-loss treatments for pets, inspired by human drugs like Ozempic and Wegovy. Okava, in partnership with Vivani Medical, is working on OKV-119, an implant that delivers exenatide to help dogs and cats lose weight. The device aims to reduce appetite without significant dietary changes, with a commercial launch expected by 2028 or 2029.
Aug 19, 2025
Ozempic is now available for U.S. patients at a reduced cash price, costing half of its previous amount - CP24
Novo Nordisk has announced that U.S. patients can now purchase a month’s supply of its diabetes drug Ozempic for $499 without insurance. This move responds to pressure from President Trump to lower drug costs. The discounted price is available through NovoCare Pharmacy and other platforms, aiming to improve access for cash-paying consumers amid ongoing concerns about medication affordability.
Aug 19, 2025
Health Canada Grants Approval for Novo's Ozempic to Lower Risk of Kidney Function Deterioration
Novo Nordisk's Ozempic, containing Semaglutide 1 mg, has received Health Canada approval to reduce the risk of kidney function decline and cardiovascular death in type 2 diabetes patients with chronic kidney disease. The approval is based on a trial showing a 24% reduction in kidney disease progression. NVO's stock sentiment remains neutral amid recent trading activity.
Aug 19, 2025
Advancements in Amylin Research May Lead to New Weight Loss Medications
A University of Oklahoma study reveals new insights into amylin receptors, which could lead to the development of blockbuster obesity drugs. The research, led by Dr. Augen Pioszak, highlights how these receptors can be targeted for better appetite control and weight loss. This advancement may aid pharmaceutical companies in developing effective drugs based on amylin.
Aug 19, 2025
The GLP-1 market continues to thrive as pharmaceutical companies and telehealth providers clash over competition.
Demand for GLP-1 drugs, including Novo Nordisk's Ozempic and Eli Lilly's weight-loss products, has surged, generating over $15 billion in sales. However, shares of Novo, Lilly, and telehealth company Hims & Hers have declined due to investor concerns. Legal challenges from Novo and Lilly against telehealth firms like Mochi Health highlight ongoing tensions over compounded drug sales and market competition.
Aug 19, 2025
Novo Nordisk reduces Ozempic's price to $499 for patients without insurance who pay in cash.
Novo Nordisk is reducing the price of its diabetes drug Ozempic to $499 for U.S. patients who self-pay or are uninsured, significantly lower than the list price of nearly $1,350. This initiative aims to improve access amid rising calls for affordable GLP-1 treatments. Ozempic, approved in 2017, helps regulate blood sugar and appetite.
Aug 19, 2025
Is the new Ozempic deal a valuable investment or simply a case of premium pricing? - Rolling Out
Novo Nordisk has launched a direct pay program for Ozempic, allowing eligible type 2 diabetes patients to access the drug for $499 monthly, bypassing insurance hurdles. While this simplifies access, affordability remains a concern, as the cost may still be prohibitive for many. The initiative reflects a broader trend in healthcare towards direct-to-consumer models, raising equity issues in medication access.
Aug 19, 2025
Avixgen, a subsidiary of Dx&Vx, secures $360 million agreement for drug delivery technology | BioWorld
Avixgen Co. Ltd., a subsidiary of Dx&Vx Co. Ltd., has secured a $360 million licensing agreement with an undisclosed U.S. biotechnology firm for its advanced cell penetrating (ACP) peptide drug delivery technology.
Aug 19, 2025
Novo Nordisk Rises Following 50% Price Cut on Ozempic and Approval for Liver Treatment
Novo Nordisk's shares rose 4% after announcing that US customers can now purchase its diabetes drug Ozempic for $499 per month, significantly lower than the previous price of $1,350. This move aims to counter competition from Eli Lilly and address political pressure over high drug costs. Additionally, Wegovy received FDA approval for treating metabolic dysfunction-associated steatohepatitis.
Aug 19, 2025
US FDA greenlights major weight loss medication for treatment of severe fatty liver disease.
The FDA has approved semaglutide, a weight-loss drug, for treating metabolic associated steatohepatitis (MASH), a severe liver condition. Initially approved for diabetes in 2017, semaglutide showed a 63% resolution rate in MASH during a phase III trial. This approval comes amid rising obesity rates, highlighting the need for effective treatments for liver diseases.
Aug 19, 2025
Pharmaceutical exports see a 14% increase in July, according to DrugsControl Media Services.
India's pharmaceuticals exports grew by 14% in July 2025, while imports rose by 13.3% compared to the same month last year. This growth reflects the increasing demand for Indian-made drugs and pharmaceuticals in the global market.
Aug 19, 2025
Exploring New Uses for GLP-1 Medications: Potential Treatments for Alcoholism and Smoking? - The Mercury News
Recent research highlights the potential of GLP-1 drugs, including semaglutide (found in Ozempic), in treating alcohol use disorder and possibly other substance use disorders. Studies show significant reductions in alcohol consumption and cravings among users. Experts emphasize the need for more effective medical interventions in addiction treatment, as current options remain limited compared to diabetes medications.
Aug 19, 2025
Canada grants approval for Ozempic to help lower the risk of advancing diabetic kidney disease.
Canada has approved Novo Nordisk's diabetes drug, Ozempic (semaglutide), to slow chronic kidney disease progression and reduce the risk of kidney failure and heart-related deaths in type 2 diabetes patients. The approval, supported by trial data showing a 24% reduction in risks, marks Ozempic as the first treatment in Canada for this dual purpose.
Aug 19, 2025
Novo Nordisk reduces the price of Ozempic to $499 for patients paying in cash - WGAL
Novo Nordisk has announced that U.S. patients can now purchase a month's supply of Ozempic, a diabetes drug, for $499 if they pay out-of-pocket. This move aims to address high drug costs amid pressure from lawmakers, including President Trump, to lower prices. The list price for Ozempic is nearly $1,000, and discounts are also available through GoodRx.
Aug 19, 2025
US patients can now access Ozempic at a reduced price if they pay in cash - AOL.com
Novo Nordisk has announced that cash-paying patients in the US can now purchase a month’s supply of its diabetes drug Ozempic for $499, significantly lower than its list price of nearly $1,000. This initiative aims to improve access amid ongoing pressure from President Trump and lawmakers to reduce drug costs. The offer is also available through GoodRx and Novo Nordisk’s website.
Aug 19, 2025
Direct-to-Consumer Approach in the Pharmaceutical Sector May Not Reduce Medication Prices
Experts warn that the pharmaceutical industry's shift to a direct-to-consumer sales model, endorsed by former President Donald Trump, is unlikely to significantly lower drug costs. While it may streamline supply chains, persistent high prices driven by research costs, marketing, and pricing strategies remain. Without regulatory reforms, any savings from this model are expected to be minimal.
Aug 19, 2025
C4IP Calls on FTC to Exercise Caution in Tackling Concerns Over Drug Pricing Issues
The Council for Innovation Promotion (C4IP) urged the Trump Administration to maintain strong patent rights, opposing measures that could weaken them under the guise of improving drug affordability. In a letter to the FTC, C4IP criticized claims made during recent listening sessions about U.S. patents and their impact on drug pricing, asserting that the patent system is crucial for drug development.
Aug 19, 2025
Genprex obtains patents in the US and Europe for its Reqorsa gene therapy targeting PD-L1 and PD-1.
Genprex, Inc. announced that the US Patent and Trademark Office has granted a Notice of Allowance for a patent covering its lead drug candidate, Reqorsa gene therapy, in combination with PD-L1 antibodies like Tecentriq. The European Patent Office has also issued a similar allowance. These patents, expiring in 2037, support Genprex's Acclaim-3 clinical trial for extensive stage small cell lung cancer.
Aug 19, 2025
After 15 Years, Tonix Receives FDA Approval for Tonmya as a Treatment for Fibromyalgia
Tonix Pharmaceuticals has received FDA approval for Tonmya (cyclobenzaprine HCl sublingual tablets) as a treatment for fibromyalgia, marking the first new drug approval in 15 years for this condition. Tonmya, set for U.S. market release in Q4 2025, showed significant pain relief in Phase 3 trials. The drug targets multiple symptoms, offering hope to the 10 million Americans affected.
Aug 19, 2025
How major pharmaceutical firms are re-evaluating their strategies – insights for start-ups - VC Magazin
The pharmaceutical industry faces challenges from the patent cliff, where major drug patents expire, leading to revenue losses as generics enter the market. The EU's proposed Unified Supplementary Protection Certificate (USPC) aims to extend patent life, offering legal certainty and cost savings. Start-ups can learn from big pharma's strategies to mitigate risks and attract investors amidst these changes.
Aug 19, 2025
Pipeline and Market Overview for Focal Segmental Glomerulosclerosis - GlobeNewswire
A new report from ResearchAndMarkets.com analyzes over 15 companies and 18 pipeline drugs targeting Focal Segmental Glomerulosclerosis (FSGS), a major cause of kidney disease. Key drugs include Sparsentan from Travere Therapeutics, DMX-200 from Dimerix Bioscience, and WAL0921 from Walden Biosciences. The report highlights ongoing clinical trials and the potential for innovative therapies in treating FSGS.
Aug 18, 2025
US patients can now access Ozempic at a reduced cost if they are able to pay upfront - WENY News
President Donald Trump is urging drugmakers to reduce high drug costs, particularly targeting popular GLP-1 drugs used for diabetes and weight loss, which are significantly more expensive in the U.S. compared to other countries.
Aug 18, 2025
Genprex Obtains Patents in the US and EU for Reqorsa Cancer Treatment Combinations | GNPX Stock Update
Genprex, Inc. has received patent allowances from the U.S. Patent and Trademark Office and the European Patent Office for its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies like Tecentriq®. These patents, expiring in 2037, enhance Genprex's intellectual property for its Acclaim-3 clinical trial targeting extensive stage small cell lung cancer.
Aug 18, 2025
UK Court of Appeal Supports Moderna's mRNA Patent in Case Against Pfizer/BioNTech - Mondaq
On August 1, 2025, the UK Court of Appeal upheld Moderna's European Patent No. 3,590,949, affirming its validity and infringement by Pfizer and BioNTech's COVID-19 vaccine, Comirnaty®. This patent covers a specific mRNA modification that enhances immune response. Moderna has pursued multiple infringement claims against Pfizer and BioNTech across various jurisdictions.
Aug 18, 2025
Avixgen, a division of Dx&Vx, has entered into a licensing agreement valued at $360 million with ...
Avixgen, a subsidiary of Dx&Vx, has signed a $360 million licensing agreement with a U.S. biotechnology company for its Advanced Cell Penetrating Peptide (ACP) drug delivery platform. This innovative technology, which effectively penetrates the blood-brain barrier, is expected to enhance CNS therapeutic development. The deal marks a significant milestone for Avixgen and Dx&Vx in global market expansion.
Aug 18, 2025
FDA Evaluates Plozasiran for Familial Chylomicronemia Syndrome Following Promising Initial Results...
The FDA is reviewing Plozasiran, a potential first-in-class therapy for Familial Chylomicronemia Syndrome (FCS), after early data shows it significantly reduces triglyceride levels. This treatment could offer new hope for patients with FCS, a rare genetic disorder linked to high triglycerides and pancreatitis risk. The review will assess Plozasiran's safety and efficacy for approval.
Aug 18, 2025
Iowa's SmartScripts faces criticism: Key details on the Ozempic counterfeit controversy - CrispNG
SmartScripts, an Iowa-based telepharmacy, faces state sanctions for distributing counterfeit Ozempic, a weight-loss drug. The Iowa Board of Pharmacy imposed a $25,000 fine and five-year probation after SmartScripts allegedly violated pharmacy laws. Owner Todd Thompson disputes the timeline, claiming he acted promptly. The company is also embroiled in multiple lawsuits, raising concerns about its future.
Aug 18, 2025
Addressing the oncology patent expiration challenge: Essential strategies for major pharmaceutical companies | BioPharma Dive
Several blockbuster oncology drugs, including Keytruda, Opdivo, and Darzalex, are approaching patent expiration, posing significant revenue risks for pharmaceutical companies. Historical data shows rapid revenue declines post-LOE, exemplified by Avastin and Gleevec. Companies like Genentech, Astellas, and Merck Sharp & Dohme (MSD) are highlighted for their varying readiness to navigate these challenges as they prepare for impending patent cliffs.
Aug 18, 2025
Novo Secures MASH Endorsement for Wegovy - BioSpace
The FDA has approved Novo Nordisk’s weight loss drug Wegovy for treating adults with metabolic dysfunction-associated steatohepatitis (MASH). This approval could potentially add $1.9 billion in revenue for Wegovy. The drug has shown efficacy in improving liver fibrosis and resolving steatohepatitis. Novo's stock rose following the announcement, despite a challenging year for the company.
Aug 18, 2025
GoodRx Partners with Novo Nordisk to Enhance Availability of Ozempic® and ...
GoodRx has partnered with Novo Nordisk to offer Ozempic® (semaglutide) and Wegovy® (semaglutide) pens to eligible self-paying patients for $499 per month, effective August 18, 2025. This collaboration aims to improve access to these in-demand GLP-1 medications for those without adequate insurance, addressing the growing demand for effective treatments for type 2 diabetes and obesity.
Aug 18, 2025
Novo Nordisk Shares Rise Following Reduction of Ozempic Price to $499 Monthly For ...
Novo Nordisk (NVO) has introduced a new offer allowing uninsured Type 2 diabetes patients to access Ozempic for $499 per month through platforms like GoodRx (GDRX) and its online pharmacy, NovoCare. This initiative aims to provide affordable access amid concerns over unsafe alternatives. Following the announcement, NVO shares rose 5%, while GDRX shares increased by 31%.
Aug 18, 2025
Novo Collaborates with GoodRx to Offer Affordable GLP-1 Medications, Reviving Direct-to-Consumer Efforts - BioSpace
Novo Nordisk has partnered with GoodRx to offer its weight loss drugs, Ozempic and Wegovy, at $499 per month for self-paying customers. This initiative aims to enhance access to the GLP-1 medications, following a previous partnership with Hims & Hers that ended due to safety concerns. The move comes as Novo seeks to regain its position in the competitive GLP-1 market.
Aug 18, 2025
What additional health issues are being addressed and researched with weight-loss medications?
Novo Nordisk's Wegovy has received U.S. approval to treat metabolic dysfunction-associated steatohepatitis (MASH), expanding its use beyond weight loss. The drug, containing semaglutide, is part of a growing market alongside Eli Lilly's Mounjaro and Zepbound, which collectively generated over $40 billion in sales last year. Other ongoing studies explore treatments for alcohol addiction, Alzheimer's, and cardiovascular diseases.
Aug 18, 2025
Novo Nordisk reduces Ozempic's price by 50% to $499 for qualifying U.S. patients paying in cash.
Novo Nordisk has reduced the monthly price of its diabetes drug Ozempic from nearly $1,000 to $499 for cash-paying U.S. patients. This move aims to enhance drug affordability and patient access, particularly for those uninsured or underinsured. The price cut follows competitive pressures and political scrutiny over drug costs, with shares of Novo Nordisk rising nearly 5% post-announcement.
Aug 18, 2025
Novo Nordisk reduces prices of weight-loss medications for customers paying out of pocket in the United States.
Novo Nordisk has reduced the price of its weight-loss drugs, Ozempic and Wegovy, to $499 per month for cash-paying customers in the US through its NovoCare platform. The company is also partnering with GoodRx to offer these drugs at the same price at pharmacies. Novo Nordisk shares rose 4%, while GoodRx shares surged over 30% following the announcement.
Aug 18, 2025
NVO Shares Rise Following FDA Approval of Wegovy for MASH: Is Further Growth Possible? - TradingView
Novo Nordisk (NVO) received FDA accelerated approval for its GLP-1 drug, Wegovy (semaglutide 2.4 mg), to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis. This marks Wegovy as the first GLP-1 therapy approved for MASH. Following the announcement, NVO shares rose 2.9%. Wegovy generated DKK 36.9 billion in sales in H1 2025.
Aug 18, 2025
Novo Nordisk shares increase following FDA approval of Wegovy for liver disease - Sherwood News
Nvidia and Advanced Micro Devices (AMD) have secured export licenses to China for previously restricted chips, agreeing to pay the U.S. government 15% of the revenue from these sales. Legal experts suggest that while the legality of this arrangement is questionable, it is unlikely to face successful challenges in court due to issues of standing and potential loopholes.
Aug 18, 2025
US patients can now access Ozempic at a reduced price if they pay in cash - WRAL.com
Novo Nordisk has announced that US patients can now purchase a month’s supply of its diabetes drug Ozempic for $499 without insurance. This move aims to address high drug costs amid pressure from President Trump. The company also offers Wegovy for the same price and has partnered with GoodRx for additional discounts.
Aug 18, 2025
US patients can now access Ozempic at a reduced price if they pay in cash.
Novo Nordisk has announced that US patients can now purchase a month’s supply of its diabetes drug, Ozempic, for $499 without insurance. This move aims to address high drug costs amid pressure from President Trump. The discounted price is available through NovoCare Pharmacy and other platforms, as the company seeks to expand access to the medication.
Aug 18, 2025
Ozempic Receives Significant Price Reduction, Leading to Surge in GoodRx Stock - TradingView
Novo Nordisk has reduced the cash price of its diabetes drug Ozempic by nearly 50% to $499 per month for uninsured patients, partnering with GoodRx to enhance accessibility. This move comes amid rising pressure from US lawmakers and follows Eli Lilly's price hike in the UK. Novo's shares surged 7.8% following the announcement, reflecting positive market reaction.
Aug 18, 2025
Novo Nordisk reduces the price of Ozempic to $499 for patients paying in cash - KCRA
Novo Nordisk has announced that U.S. patients can now purchase a month's supply of Ozempic, a diabetes drug, for $499 if they pay out-of-pocket. This move aims to address high drug costs amid pressure from lawmakers, including President Trump, to lower prices. The list price for Ozempic is nearly $1,000, and discounts are also available through GoodRx.
Aug 18, 2025
Four individuals apprehended in Jaipur for possession of prohibited medications, according to DrugsControl Media Services.
The Central Narcotics Bureau (CBN) has seized a large shipment of banned medicines, including Tramadol capsules, Alprazolam tablets, and Codeine Phosphate, in Jaipur. Four individuals have been arrested in connection with the illicit trafficking of these substances.
Aug 18, 2025
Unlicensed pharmaceutical manufacturing facility shut down, according to DrugsControl Media Services.
The Drugs Department sealed an unlicensed factory in Lodhwan, Nurpur, after discovering 23,000 unauthorized injections during a raid. The operation was led by Drug Inspector Pyar Ch.
Aug 18, 2025
CSPC Megalith Biopharmaceutical identifies novel ADCs targeting TROP2 - BioWorld
CSPC Megalith Biopharmaceutical Co. Ltd. has announced the discovery of new antibody-drug conjugates (ADCs) targeting TROP2, which are linked to cytotoxic drugs. These ADCs show potential for treating pancreatic and breast cancer, leveraging the anti-tumor-associated calcium signal transducer 2 (TACSTD2) antibodies.
Aug 18, 2025
Yuhan's lung cancer medication aims for significant sales by 2027 - KED Global
Yuhan Corp.'s lung cancer drug, Lazertinib (marketed as Leclaza in South Korea), has received FDA approval for global use as a combination therapy with Johnson & Johnson's treatment. This marks a significant milestone for Yuhan in expanding its presence in the oncology market.
Aug 18, 2025
Generative AI Creates Innovative Antibiotics - But Who Holds the Patent Rights? - Mondaq
Researchers at the Broad Institute of MIT and Harvard have utilized generative AI to design novel antibiotics, NG1 and DN1, targeting drug-resistant pathogens Neisseria gonorrhoeae and Staphylococcus aureus. This breakthrough highlights the potential of AI in drug discovery, although questions about patent ownership remain following a UK Supreme Court ruling on AI inventorship.
Aug 17, 2025
Eli Lilly: A Biotech Leader Transforming Long-Term Growth Strategies - AInvest
Eli Lilly (LLY) is redefining long-term value in the healthcare sector with its blockbuster drugs Mounjaro and Zepbound, which generated significant revenue in Q2 2025. The company’s robust R&D pipeline and $27 billion investment in U.S. manufacturing position it for sustained growth despite pricing pressures. LLY's strategic focus on innovation and infrastructure makes it a compelling investment opportunity.
Aug 17, 2025
A study reveals that affluent nations spend more on vital medications, yet their financial strain is significantly less.
A new study published in JAMA Health Forum reveals that while wealthy countries pay higher list prices for essential medicines, their purchasing power results in lower overall costs. In contrast, poorer nations face a greater financial burden despite lower list prices. The study analyzed 549 essential medicines, including tenofovir disoproxil and paclitaxel, highlighting disparities in affordability across regions.
Aug 17, 2025
Editorial | China's Biotechnology Sector Outpaces America's in Cost and Speed - The New York Times
China's biotech industry is emerging as a potential solution for rising drug costs in the U.S., offering cheaper medications for diseases like diabetes, cancer, and heart disease. Increased competition could lower prices and spur innovation. Despite challenges in healthcare access and drug development, China's significant investments in biotech aim to address its aging population and health crises.
Aug 17, 2025
Eli Lilly's Dominance in the Obesity Market Encounters Internal and External Challenges - AInvest
Eli Lilly reported strong Q2 results for its obesity drugs Mounjaro and Zepbound, with revenues up 38% to $15.56 billion. However, its oral weight-loss pill Orforglipron underperformed in trials, raising concerns. Competitor Viking Therapeutics is developing VK-2735, a dual GLP-1/GIP agonist, which could threaten Lilly's market share with promising results in Phase 2 trials.
Aug 17, 2025
Merck Shares: Consider Purchasing During Market Lows Despite Obstacles - AInvest
Merck & Co., Inc. (MRK) faces challenges due to the impending loss of exclusivity for its key drug, Keytruda, and costly acquisitions, resulting in a 15.7% underperformance this year. However, positive Phase 3 trial results for Keytruda in bladder cancer and a strong pipeline suggest potential long-term growth, making it an attractive investment opportunity for shareholders.
